Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 4 institutions in 2 countries.
Luping PangResearch Center of Basic Medicine, Academy of Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0002-8224-9250
Stijn LendersBiocrystallography, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 822, 3000 Leuven, Belgium.ORCID 0000-0002-8833-9353
Evgenii M OsipovBiocrystallography, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 822, 3000 Leuven, Belgium.
Stephen D WeeksBiocrystallography, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 822, 3000 Leuven, Belgium.ORCID 0000-0002-1360-0852
Jef RozenskiMedicinal Chemistry, Rega Institute for Medical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 1030, 3000 Leuven, Belgium.ORCID 0000-0001-9624-5536
Tatiana PillerLaboratory of Microbiology, Parasitology and Hygiene, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.ORCID 0000-0003-1266-9513
Davie CappoenLaboratory of Microbiology, Parasitology and Hygiene, Department of Pharmaceutical Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium.
Sergei V StrelkovBiocrystallography, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 822, 3000 Leuven, Belgium.ORCID 0000-0001-7189-4652
Arthur Van AerschotMedicinal Chemistry, Rega Institute for Medical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Herestraat 49, P.O. Box 1030, 3000 Leuven, Belgium.ORCID 0000-0003-3528-8588
KU Leuven · BERega Institute for Medical Research · BEUniversity of Antwerp · BEZhengzhou University · CN
Funding
KU Leuven Research Fund 3M14022Research Foundation - Flanders 1S68722NResearch Foundation - Flanders G066619NResearch Foundation - Flanders G0A4616N
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural Basis of Cysteine Ligase MshC Inhibition by Cysteinyl-Sulfonamides. · full record | OpenQuestion